Tian Daxue, Li Nan, Huang Wei, Zong Huantao, Zhang Yong
Urology Department, Beijing Tian Tan Hospital, Capital Medical University, Neurourology Research Division, China National Clinical Research Center for Neurological Disease, Beijing, China.
Urology Department, Beijing Tian Tan Hospital, Capital Medical University, Neurourology Research Division, China National Clinical Research Center for Neurological Disease, Beijing, China.
J Pediatr Surg. 2017 Feb;52(2):360-365. doi: 10.1016/j.jpedsurg.2016.10.003. Epub 2016 Oct 14.
We carried out a systematic review and meta-analysis to evaluate the efficacy and safety of adrenergic alpha-antagonists as a medical expulsive therapy for ureteral stones in pediatric patients.
The PubMed, EMBASE and Cochrane Controlled Trials Register databases were searched up to January 2016. All randomized controlled trials and all cohort studies in which patients were randomized to receive either adrenergic alpha-antagonists or placebo for ureteral stones were identified. The outcome measures assessed were overall stone expulsion rate (primary), expulsion time (secondary), and treatment-emergent adverse events.
Five trials with a total of 406 pediatric patients met the inclusion criteria. According to the doses of adrenergic alpha-antagonists, the pooling effects of adrenergic alpha-antagonists were analyzed, with a higher expulsion rate obtained than in controls, the stone expulsion rate (OR=2.70, 95% CI 1.49 to 4.91, P=0.001). Adrenergic alpha-antagonists statistically did not significantly decrease the number of the stone expulsion time with the placebo, the stone expulsion time (SMD=-4.65, 95% CI -9.76 to 0.45, P=0.07). Safety assessments included common treatment-emergent adverse events (TEAEs) (OR=2.01, 95% CI 0.74 to 5.48, P=0.17). Compared with placebos, there was a higher stone expulsion rate with the adrenergic alpha-antagonists; in addition, fewer adverse effects were observed.
This meta-analysis may suggest that adrenergic alpha-antagonists are a safe and effective medical expulsive therapy choice for ureteral stones in pediatric patients. As the level of classification of evidence-based medicine, the level of evidence of our article is Ia. But it remains to need a large-scale multicenter randomized controlled study to be further confirmed.
The level of evidence of our study is V.
我们进行了一项系统评价和荟萃分析,以评估肾上腺素能α受体拮抗剂作为小儿输尿管结石药物排石疗法的疗效和安全性。
检索截至2016年1月的PubMed、EMBASE和Cochrane对照试验注册数据库。确定所有随机对照试验以及所有将患者随机分为接受肾上腺素能α受体拮抗剂或安慰剂治疗输尿管结石的队列研究。评估的结局指标包括总体结石排出率(主要指标)、排出时间(次要指标)和治疗中出现的不良事件。
共有5项试验、406例儿科患者符合纳入标准。根据肾上腺素能α受体拮抗剂的剂量,分析了其合并效应,结石排出率高于对照组,结石排出率(OR=2.70,95%CI 1.49至4.91,P=0.001)。与安慰剂相比,肾上腺素能α受体拮抗剂在统计学上并未显著缩短结石排出时间,结石排出时间(SMD=-4.65,95%CI -9.76至0.45,P=0.07)。安全性评估包括常见的治疗中出现的不良事件(TEAEs)(OR=2.01,95%CI 0.74至5.48,P=0.17)。与安慰剂相比,肾上腺素能α受体拮抗剂的结石排出率更高;此外,观察到的不良反应更少。
这项荟萃分析可能表明,肾上腺素能α受体拮抗剂是小儿输尿管结石安全有效的药物排石治疗选择。作为循证医学的分类级别,我们文章的证据级别为Ia级。但仍需要大规模多中心随机对照研究进一步证实。
我们研究的证据级别为V级。